Published in Hepatitis Weekly, January 16th, 2006
In line with the company's decision to withdraw its marketing authorization application (MAA) in Europe, it has also closed its operations in Europe. Nabi Biopharmaceuticals remains committed to advancing the commercialization of PhosLo (calcium acetate) and Hebig in Europe and, upon their approval, the company's focus will be on the launch of these two critical therapies through a sales...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.